GlaxoSmithKline and NEOMED partner to create new biologics and vaccine centre of excellence

Date Closed: 3/31/2015

Value: C$47 million

On March 31, 2015, GlaxoSmithKline (GSK) announced the launch of the biologics and vaccine centre of excellence in Laval under a proposed partnership with NEOMED Institute. This Centre will be unique in Canada and GSK has committed $47 million towards its establishment.

As part of the new partnership, GSK and NEOMED say they will each invest $10 million to fund up to five product research and development projects transferred from GSK. GSK will continue to pay the entire cost for leasing the facility for-five years, representing an investment of $10 million. Additionally, GSK will buy clinical testing services from the Contract Research Institute which will be part of the Centre of Excellence, for at least three years representing an additional investment of $27 million.

NEOMED, headquartered Montreal, Quebec is a not-for-profit organization who fosters the development of promising therapeutic approaches emerging from academia and biotechnology companies.

GSK, headquartered in Mississauga, Ontario, is a research-based pharmaceutical and healthcare company.

BLG represented GSK with a team led by John Godber that included Manon Gauthier, Andrew Loh and Catherine Guertin